Apyx Medical Corp (APYX) Stock Price & Analysis

Apyx Medical Corp (APYX) fell 0.33% to USD 3.05 as of September 8, 2026 at 12:04 UTC, according to Nexqual real-time market data.

APYX last closed at USD 3.05; the session ranged USD 3.02–3.08 on volume of 62,059 shares. Market capitalization is —, with a 52-week range of USD 1.7–5.08 (NMS). Source: Nexqual, September 8, 2026 at 12:04 UTC.

Key Statistics (as of September 8, 2026 at 12:04 UTC)

Technical Analysis (APYX)

Nexqual's technical model rates APYX "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 12:04 UTC.

From Apyx Medical Corp's Latest SEC 10-K Filing (filed 2026-03-10)

Key Strengths & Strategy (as disclosed to the SEC)

• We anticipate receiving clearance in the second quarter 2026.   Competition   Currently, we are the only company with helium-based plasma products and four specific indications from the FDA. With the launch of AYON, we now compete directly with companies that have devices that perform liposuction procedures.
• It also continues to be the subject of numerous presentations at traditional and cosmetic surgery conferences around the world.   This technology initially received FDA clearance in 2012 and a CE mark in December 2014, which enables us to sell our technology in the European Union.
• During 2021, we began to launch these new handpieces in our international markets, designed specifically for minimally invasive use, with improved ergonomics and safety features.   AYON Body Contouring System   AYON is an FDA-cleared device that provides the surgeon with an all-in-one system to perform any surgical procedure needed in their offices or surgical suite.
• We feel that our products and our strategy as a customer-centric aesthetic medical device manufacturer have, and will continue to improve, the lives of doctors and their patients.   Intellectual Property   We rely on our intellectual property that we have developed or acquired over the years including patents, trade secrets, technical innovations and various licensing agreements to provide our future growth and build our competitive position.

Partnerships

• In connection with the Asset Purchase Agreement with Symmetry Surgical in 2018, we entered into a Manufacturing and Supply Agreement for a ten-year term, pursuant to which we manufacture certain products and sell to them at agreed upon prices.
• The facility also distributes products directly to customers in certain international markets and provides warranty and repair services.   Joint Venture   In 2019, we executed a joint venture agreement with its Chinese supplier whereby we have a 51% ownership interest, to establish a presence in the Chinese market for the manufacturing and sale of our Surgical Aesthetics products.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 12:04 UTC. This page is informational and not investment advice.